Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar Antipopnfresh100 (73.23) Submitted: 4/8/2010 8:56:07 PM : Underperform Start Price: $35.84 ACOR Score: +48.13

Run-up, high current, high book

Featured Broker Partners


Advertisement